In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 2.57 below Pulmonx Corporation average.

Within Medical Equipment & Supplies industry 62 other companies have achieved higher Quick Ratio than Pulmonx in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 849 to 1040.

Explain Quick Ratio?
How much Cash & cash equivalents LUNG�s has?
What are LUNG�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/LUNG/financial-strength

https://api.csimarket.com/api/v1/companies/LUNG/fundamentals

https://api.csimarket.com/api/v1/companies/LUNG/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

LUNG Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-9.35 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-30.44 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	2.57	Subscribe	Subscribe	Subscribe	Subscribe
LUNG's Total Ranking	# 1040	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	1.64 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-5.58 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 63
Healthcare Sector	# 417
Overall Market	# 1040

Quick Ratio Statistics
High	Average	Low
18.49	6.42	2.44
(Dec 31 2020)		(Dec 31 2019)

Financial Statements
Pulmonx's Current Liabilities	$ 21 Millions	Visit LUNG's Balance sheet
Pulmonx's Cash & cash equivalent	$ 53 Millions	Visit LUNG's Balance sheet
Source of LUNG's Sales		Visit LUNG's Sales by Geography

Cumulative Pulmonx's Quick Ratio

LUNG's Quick Ratio for the trailling 12 Months

LUNG Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-15.41 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-19 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	3.01	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3793	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-2.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-8.82 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to LUNG Financial Strength Comparisons >> Go to Compare LUNG Quick Ratio to its Competitors

News about Pulmonx Corporation Quick Ratio

Pulmonx Corporation Grants Inducement Awards to New Chief Financial Officer

Pulmonx Corporation Grants Inducement Awards to New Chief Financial Officer
Pulmonx Corporation, a leading global provider of minimally invasive treatments for lung disease, recently announced the granting of inducement awards to Mehul Joshi, who was appointed as the company s Chief Financial Officer in April 2024. The awards, approved by the Compensation Committee of the Board of Directors, include a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock.
This strategic move by Pulmonx reflects the company s commitment to attracting and retaining top talent in key leadership positions. By offering inducement awards to new executives, Pulmonx aims to incentivize performance and drive shareholder value. The appointment of Mehul Joshi as Chief Financial Officer brings a wealth of experience and expertise to the company, further strengthening its leadership team.

On the trailing twelve months basis In spite of the year on year decrease in LUNG's Current Liabilities to $20.74 millions, cumulative Quick Ratio to 3.01 below the LUNG average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 193 other companies have achieved higher Quick Ratio than Pulmonx. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3761 to 3793.

Explain Quick Ratio?
How much Cash & cash equivalents LUNG�s has?
What are LUNG�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Equipment & Supplies Industry	# 194
Healthcare Sector	# 872
Within the Market	# 3793

trailing twelve months Quick Ratio Statistics
High	Average	Low
13.21	6.52	3.14
(Sep 30 2021)		(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Equipment & Supplies Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Ceribell Inc	6.51	$ 117.467 Millions	$ 18.034 Millions
Autonomix Medical Inc	6.13	$ 7.692 Millions	$ 1.254 Millions
Iradimed Corporation	6.13	$ 63.288 Millions	$ 10.323 Millions
Orasure Technologies Inc	5.90	$ 148.238 Millions	$ 25.104 Millions
Perspective Therapeutics Inc	5.09	$ 201.695 Millions	$ 39.602 Millions
Clearpoint Neuro Inc	4.68	$ 46.184 Millions	$ 9.869 Millions
Cvrx inc	4.67	$ 58.746 Millions	$ 12.583 Millions
Dexcom Inc	4.25	$ 964.800 Millions	$ 227.000 Millions
Innovative Eyewear Inc	3.86	$ 3.197 Millions	$ 0.829 Millions
Sight Sciences Inc	3.84	$ 77.402 Millions	$ 20.137 Millions
Alpha Pro Tech Ltd	3.78	$ 25.546 Millions	$ 6.750 Millions
Hyperfine Inc	3.60	$ 37.872 Millions	$ 10.532 Millions
Profound Medical Corp	3.41	$ 33.343 Millions	$ 9.771 Millions
Rxsight Inc	3.40	$ 254.683 Millions	$ 74.952 Millions
Omada Health Inc	3.23	$ 243.151 Millions	$ 75.379 Millions
Transmedics Group Inc	3.22	$ 492.962 Millions	$ 152.857 Millions
Trisalus Life Sciences Inc	3.15	$ 41.057 Millions	$ 13.014 Millions
Procept Biorobotics Corporation	3.10	$ 218.369 Millions	$ 70.353 Millions
Carlsmed Inc	3.08	$ 56.207 Millions	$ 18.237 Millions
Outset Medical Inc	3.07	$ 136.627 Millions	$ 44.453 Millions
Sharps Technology Inc	2.82	$ 7.478 Millions	$ 2.650 Millions
Edwards Lifesciences Corporation	2.81	$ 4,683.700 Millions	$ 1,664.300 Millions
Mimedx Group Inc	2.81	$ 120.791 Millions	$ 43.031 Millions
Pulse Biosciences Inc	2.74	$ 36.725 Millions	$ 13.395 Millions
Staar Surgical Co	2.73	$ 206.414 Millions	$ 75.541 Millions
Medinotec Inc	2.68	$ 2.584 Millions	$ 0.963 Millions
Glaukos Corp	2.66	$ 337.478 Millions	$ 126.726 Millions
Pulmonx Corporation	2.57	$ 53.245 Millions	$ 20.739 Millions
Beta Bionics Inc	2.48	$ 81.551 Millions	$ 32.836 Millions
Irhythm Holdings Inc	2.46	$ 560.719 Millions	$ 228.025 Millions

Date modified: 2026-11-04T15:20:27+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.